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Background: Macrolides are antibiotics that have anti-inflammatory activities. 
Hence, they are used for both acute and chronic inflammatory airway diseases. 
However, the effects of these agents on allergic airway disorders presenting with 
an isolated chronic cough, such as non-asthmatic eosinophilic bronchitis and 
eosinophilic tracheobronchitis with cough hypersensitivity (atopic cough), still 
remain to be elucidated. 
Objective: To determine if macrolides are effective in the management of 
chronic cough caused by eosinophilic airway inflammation. 
Methods: The cough reflex sensitivity to inhaled capsaicin was measured at 48 
h after challenge with an aerosolized antigen in actively sensitized guinea pigs. 
The 14-, 15- or 16-membered macrolides (erythromycin, azythromycin, or 
josamycin, respectively) were given intraperitoneally every 12 h after the antigen 
challenge. Bronchoalveolar lavage and the resection of the tracheal tissue were 
performed immediately after the measurement of the cough response to 
capsaicin. 
Results: The antigen-induced increase in the number of coughs elicited by 
capsaicin inhalation was significantly reduced by treatments with erythromycin 
and azythromycin, but not with josamycin. Erythromycin dose-dependently 
inhibited the increases in the substance P, prostaglandin E2 and leukotriene B4 
levels, but not the histamine levels, in the bronchoalveolar lavage fluid. However, 
erythromycin did not influence the antigen-induced decrease in the neutral 
endopeptidase (NEP) activity in the tracheal tissue. 
Conclusions: Both 14- and 15-membered, but not 16-membered, macrolides 
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 could reduce the antigen-induced cough reflex hypersensitivity by inhibiting the 
antigen-induced release of the afferent sensory nerve sensitizers. These 
macrolides may be therapeutically useful for the treatment of isolated chronic 
cough based on cough reflex hypersensitivity in allergic airway diseases such as 
non-asthmatic eosinophilic bronchitis and atopic cough. 
 
Key words 
macrolide antibiotics, cough response, eosinophilic airway inflammation, 
substance P, prostaglandin E2, capsaicin 
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 1. Introduction 
Chronic cough is one of the most common and distressing symptoms of 
respiratory diseases. One of the most representative airway disorders 
responsible for chronic cough is eosinophilic bronchitis [1], including bronchial 
asthma, non-asthmatic eosinophilic bronchitis (NAEB) [2], atopic cough (AC) [3], 
and cough variant asthma (CVA) [4]. Coughs are caused by cough reflex 
hypersensitivity in NAEB and AC. Moreover, the cough reflex hypersensitivity in 
these patients, which is suggested to be associated with sensory neuropeptides 
and chemical mediators such as arachidonic acid metabolites [5-7], histamine [8] 
and platelet activating factor (PAF), can become normalized after successful 
treatment [9], such as with corticosteroids and antihistamines. However, some of 
these patients experience persisting cough despite high levels of these 
medications, and therefore, they are severely impaired in their quality of life. 
Unfortunately, no effective therapy for such patients has yet been clearly 
established. Although affecting only a small proportion of all NAEB and AC 
sufferers, this problem is therefore crucial for clinicians. 
Macrolide antibiotics (herein referred to as ‘macrolides’) are a 
well-characterized family of spectrum antimicrobials that are used to treat acute 
bacterial infections. Moreover, it has been shown that 14- and 15-membered, but 
not 16-membered, macrolides [10] possess immunomodulatory and 
anti-inflammatory activities to inhibit migration of neutrophils, production of 
reactive oxygen radicals and mucus hypersecretion. Such properties other than 
the antibiotic actions have been well studied and applied to the therapy for 
chronic neutrophilic inflammatory airway diseases, including diffuse 
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 panbronchiolitis (DPB) [11] and sinobronchial syndrome (SBS) [12]. In addition, 
the effects of macrolides on bronchial asthma have been investigated in recent 
clinical studies [13-16]. These studies demonstrated that, in bronchial asthma, 
although the effects of macrolides on bronchcoconstriction remain controversial, 
the symptom score, including cough, was observed to improve [13, 15] by 
treatment with these agents. However, there have so far not been any reports 
concerning the effects of macrolides on the cough reflex hypersensitivity 
associated with the eosinophilic inflammatory airway diseases, such as NAEB 
and AC.  
In this study, we investigated the effects of erythromycin (EM), azythromycin 
(AZM) and josamycin (JM), the representative agents for 14-, 15-, and 
16-membered macrolides, respectively, on cough reflex sensitivity to inhaled 
capsaicin in an animal model of airway allergic inflammation with cough reflex 
hypersensitivity. We also examined the effects on the levels of chemical 
mediators and substance P (SP) in the bronchoalveolar lavage fluid (BALF) and 
neutral endopeptidase (NEP) activity in the tracheal tissue. 
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 2. Methods 
2.1 Animals 
 Male, albino, Hartley-strain guinea pigs weighing 200 to 220 g were obtained 
from the Sankyou Laboratory Service (Toyama, Japan). They were then 
quarantined in the Animal Research Center of Kanazawa University. All animal 
procedures carried out during this study complied with the standards set out in 
the Guidelines for the Care and Use of Laboratory Animals at the Takara-machi 
Campus of Kanazawa University. The total n value in this study was 144; namely, 
40 for Experiment A, 24 for Experiment B, 24 for Experiment C, 40 for 
Experiment D and 16 for Experiment E. 
 
2.2 Study design 
Three experimental groups (including Experiments A, B and C) were set at 
different times, respectively. Guinea pigs in each experimental group were in 
turn assigned to negative control (NC) groups, positive control (PC) groups and 
macrolides (EM for Experiment A, AZM for Experiment B or JM for Experiment 
C) groups (n = 8 for each group). The animals in the PC and macrolides groups 
were then actively sensitized and exposed to aerosolized antigens. In addition, 
the animals in the NC groups were exposed to aerosolized saline. 
Every 12 h after the antigen challenge (total; four times), 2.5 ml/kg of EM 
solution at concentrations of 0.2, 2 or 20 mg/ml (final dose: 0.5, 5 or 50 mg/kg, 
respectively), AZM solution at a concentration of 20 mg/ml (final dose: 50 mg/kg) 
or JM solution at a concentration of 20 mg/ml (final dose: 50 mg/kg) were 
intraperitoneally administered to the animals in the macrolides groups. The 
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 animals in PC and NC groups were given the intraperitoneal vehicle (2.5 ml/kg of 
distilled water). At 48 h after the antigen or saline challenge, the cough reflex 
sensitivity to inhaled capsaicin was measured.  
After the measurement of the cough reflex sensitivity, bronchoalveolar lavage 
(BAL) was performed, and then the tracheal segments (80 to 120 mg each) were 
resected and isolated from the animals. However, to investigate the effects of 
EM on the substance P (SP) levels in the BAL fluid (BALF), another experimental 
group (Experiment D) set-up was needed to avoid the influence of capsaicin 
inhalation. The NC, PC and macrolides group in Experiment D were performed 
under the same conditions as those in Experiment A, but they were not 
subjected to capsaicin provocation before the performance of BAL (n =8 for each 
group). 
In addition, to investigate the effects of EM on the normal cough reflex 
sensitivity, Experiment E was also newly developed. The guinea pigs in 
Experiment E were not sensitized and they received either 2.5 ml/kg of EM 
solution at a concentration of 20 mg/ml (final dose: 50 mg/kg) or distilled water in 
the same manner as that used for experiment A (n = 8, respectively). At 48 h 
after the first administration of either EM or vehicle, the cough reflex sensitivity to 
inhaled capsaicin was then measured. 
 
2.3 Active sensitization 
The guinea pigs were actively sensitized to ovalbumin (OA) using a 
modification of the method described by Muraki et al. [17]. Briefly, each animal 
was pretreated with the intraperitoneal administration of 30 mg/kg of 
 8
 cyclophosphamide. Two days later, the animals were immunized with 2.0 mg of 
OA and 100 mg of aluminum hydroxide [Al(OH)3]. A booster injection of 0.01 mg 
of OA and 100 mg of Al(OH)3 was then carried out three weeks after the primary 
immunization. The naïve guinea pigs that were kept in the same surroundings as 
the active sensitization animals that were used for NC. 
 
2.4 Antigen challenge. 
Three weeks after the booster injection, the actively sensitized guinea pigs 
were intraperitoneally administered 20 mg/kg of diphenhydramine to avoid the 
onset of acute anaphylactic respiratory distress. Thirty minutes later, the 
conscious guinea pigs were challenged for 90 seconds with 10 mg/ml OA 
aerosol by a method described previously [6, 18, 19]. The animals in the NC 
group were not injected with diphenhydramine, but they did inhale aerosolized 
saline by the same method as that described for the sensitized guinea pigs. In 
addition, the cough response to inhaled capsaicin was measured 48 h after the 
antigen challenge. 
 
2.5 Measurement of cough reflex sensitivity 
Cough reflex sensitivity was measured by a method as described previously [6]. 
Briefly, each conscious guinea pig was placed in an airtight custom-built 
transparent plastic box consisting of a head chamber (volume 1600 ml) isolated 
from the body chamber. The pressure in the body chamber was recorded. 
Coughs were detected as a transient specific change in the pressure (a rapid 
inspiration followed by rapid expiration). To disregard the motion- and 
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 sneezing-related changes in the pressure, we visually monitored the movements 
of the guinea pigs. Progressively increasing concentrations of the capsaicin 
solution (10-6, 10-4 M) were inhaled by the animals for 2 min from a Devilbiss 646 
nebulizer (Devilbiss Co., Somerset, PA, USA) operated by compressed air at 1.6 
l/min (Iwaki Air Pump AP-115AN, Iwaki Co. Ltd, Tokyo, Japan). The nebulizer 
output was 0.037 ml/min. Coughs were counted by a trained observer and 
recognized by both the transient change in the pressure within the box and the 
characteristic animal posture. The number of coughs was counted during a 
2-minute inhalation of each capsaicin solution and for an additional one-minute 
observation (n=8 in each group). In addition, we examined the effect of EM on 
the cough reflex sensitivity in the naïve guinea pigs. 
 
2.6 Bronchoalveolar lavage (BAL) 
BAL was performed immediately after analyzing the cough reflex sensitivity to 
capsaicin by a method as described previously [18, 19]. Briefly, the guinea pigs 
were anaesthetized by the intraperitoneal injection of 75 mg/kg of sodium 
pentobarbital and they were placed in a supine position. Through the tracheal 
cannula the lungs were lavaged with 10 ml of saline solution (0.15 mM NaCl) 2 
times (total: 20 ml). 
 
2.7 Bronchoalveolar lavage fluid (BALF) analysis 
The cells in the BALF were immediately stained with Turk solution and counted 
in duplicate with a hemocytometer (in a Burker chamber). Different cell counts 
(analyzing 300 cells) were made on a smear prepared by cytocentrifugation and 
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 stained with Wright-Giemsa. Subsequently, the BALF was centrifuged (1500 rpm 
for 10 min) and the supernatants were stored at -80 °C. For measurement of the 
SP levels in the BALF, we performed BAL and treated the BALF in another 
experimental set-up in which the guinea pigs were not subjected to capsaicin 
provocation at 48 h after the antigen challenge. 
 
2.8 Concentration of SP, prostaglandin E2, histamine, leukotriene B4 and 
thromboxane B2 in BALF 
SP, prostaglandin E2 (PGE2), histamine, and leukotriene B4 (LTB4) levels in the 
BALF were determined by using a commercial enzyme immunoassay (EIA) kit. 
Thromboxane B2 (TXB2) levels in the BALF were measured by a commercial 
TXB2 [125I] radioimmunoassay (RIA) kit. 
 
2.9 Neutral endopeptidase (NEP) activity of tracheal tissue 
The removed trachea was soaked in saline and homogenized by an ultrasonic 
homogenizer (SONIFIER 250, Branson Ultrasonics, Danbury, CT). The sample 
was centrifuged at 5000 rpm for 2 minutes. The supernatant was used as a 
tracheal sample. 
The NEP activity in the tracheal sample was determined by a two-step 
reaction method as described previously [20], using the 
substratesuccinyl-alanyl-alanyl-phenylalanyl-para-nitroanilide 
(Suc-Ala-Ala-Phe-p NA). Briefly, a total of 100 μl of the tracheal samples were 
incubated with Suc-Ala-Ala-Phe-p NA (final concentration: 4 mmol/l in Tris-HCl 
[Sigma], pH 7.4) as the substrate in the presence or absence of 
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 phosphoramidon (final concentration: 2 μmol/l). The reaction (total volume: 250 
μl) was measured in duplicate in a 96-well microtiter plate at room temperature. 
The increase in specific absorbance at 405 nm (as a result of the accumulation 
of free p-nitroaniline) was determined at several time points (0-24 h) using a 
plate reader (EAR 340AT, SLT-Labinstruments, Grödiq, Austria). Several 
concentrations of aminopeptidase solution were used to construct the standard 
curve. The NEP activity was determined as the activity that could be inhibited by 
phosphoramidon and it was expressed as units/mg in reference to the standard 
curve. One unit represents the enzyme activity that is able to separate 1 
μmol/min p NA from Suc-Ala-Ala-Phe-p NA at pH 7.4 at 25 °C. 
 
2.10 Reagent 
The following chemicals were used: ovalbumin (Sigma, St. Louis, MO), 
erythromycin (Abbott Japan Co., Ltd., Tokyo, Japan), azythromycin (LKT 
Laboratories, Inc. St. Paul, MN), josamycin (Astellas Pharm. Inc., Tokyo, Japan), 
cyclophosphamide (Shionogi Co., Ltd., Osaka, Japan), aluminum hydroxide 
(Wako Pure Chemical Ind. Osaka, Japan), diphenhydramine (Wako Pure 
Chemical Ind.), saline (Otsuka Pharmaceutical Co., Ltd., Osaka, Japan), 
capsaicin (Sigma), sodium pentobarbital (Abbott laboratories, North Chicago, IL), 
SP emzyme immunoassay (EIA) kit (CAYMAN chemical company, MI, USA), 
PGE2 EIA kit (R&D Systems, Minneapolis, MN), histamine EIA kit (Immunotech 
a.s., Praha, CR), LTBB4 EIA kit (CAYMAN chemical company), TXB2 [ I] RIA kit 
(NEN Life Science Products, Inc., Boston, USA), Suc-Ala-Ala-Phe-p NA (Sigma), 




2.11 Statistical analysis 
All the data are shown as the mean ± S.E.M. The differences among all groups 
for each experiment were analyzed using the Kruskal Wallis test. If the Kruskal 
Wallis test was positive (P < 0.05), then the differences between any pair of 
groups in each experiment were analyzed using the Mann-Whitney U test 
(StatView 5.0 software program, SAS Institute Inc., Cary, NC), with the level of 
significance set at P < 0.05. 
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 3. Results 
3.1 Effects of macrolides on cough reflex sensitivity 
The number of coughs, induced by 1.0 × 104 M of capsaicin, was significantly (P 
< 0.01) increased in the sensitized group that was administered distilled water 
(PC group) in comparison to the NC group (see Figure 1A, 1C and 1D). EM both 
significantly and dose-dependently inhibited the antigen-induced increase in the 
number of coughs (P < 0.01) (see Figure 1A). Although AZM also inhibited the 
antigen-induced increase in the number of coughs (P < 0.05) (see Figure 1C), 
JM showed no such inhibition (see Figure 1D). 
The number of coughs induced by 1.0 × 106 M of capsaicin did not significantly 
differ between the NC, PC and macrolides groups (EM, AZM, JM, respectively) 
(see Figure 1A, 1C and 1D). 
EM did not affect the number of capsaicin-induced coughs in the naïve 
guinea-pigs (see Figure 1B). 
 
3.2 Effects of macrolides on BALF cells 
The total number of cells and the percentage of neutrophils and eosinophils in 
the BALF increased significantly in the PC group in comparison to the NC group 
(P < 0.01 and P < 0.01, respectively). EM inhibited the increase in the total 
number of cells dose-dependently (P < 0.01), whereas the percentage of 
neutrophils or eosinophils was unchanged (see Table 1A). Likewise, AZM also 
inhibited the increase in the total number of cells (P < 0.05), and did not 
influence the proportion of leukocytes in the BALF (see Table 1B). JM did not 
affect either the total number of cells or the proportion of leukocytes in the BALF 
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 (see Table 1C).  
 
3.3 Effects of EM on the concentrations of SP, PGE2, LTBB4, histamine, and 
TXB2 in the BALF 
The concentration of SP in the BALF increased greatly in the PC group in 
comparison to the NC group (P < 0.01). EM significantly inhibited the increase in 
the SP levels in a dose dependent manner (P < 0.05) (see Figure 2A). 
The PGE2 levels also increased significantly in the BALF of the PC group in 
comparison to the NC group (P < 0.05). EM inhibited the antigen-induced PGE2 
increase in the BALF in a dose dependent manner (P < 0.01) (see Figure 2B). 
The LTBB4 levels in the BALF increased significantly in the PC group in 
comparison to the NC group (P < 0.05). EM inhibited the antigen-induced LTB4B  
increase in the BALF in a dose dependent manner (P < 0.05) (see Figure 2C). 
The histamine levels also increased significantly in the BALF of PC group in 
comparison to the NC group (P < 0.05). EM did not significantly affect the 
antigen-induced histamine increase in the BALF (see Figure 2D). 
The TXB2 levels in the BALF did not increase in the PC group in comparison to 
the NC group, and EM did not alter the TXB2 levels in the BALF (data not 
shown). 
 
3.4 Effect of EM on NEP activity 
NEP activity decreased significantly in the PC group in comparison to the NC 
group (P < 0.05). EM did not prevent the decrease in the NEP activity of the 
tracheal tissue following the antigen challenge (see Figure 3). 
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 4. Discussion 
Macrolides, especially 14- and 15-membered macrolides [10], have separate 
and distinct antibiotic and anti-inflammatory actions. Several reports have shown 
that 14- and 15-membered macrolides also affect the arachidonic acid cascade 
[21, 22], which is associated with an increase in the cough reflex sensitivity. 
However, the effects of macrolides on coughing resulting from cough reflex 
hypersensitivity, which is characteristic of NAEB and AC patients, have never 
been investigated. Therefore, in this study, we tested macrolides in an 
established experimental model of airway eosinophilic inflammation with cough 
reflex hypersensitivity [6]. The absence of the involvement of 
bronchoconstriction in the cough response to inhaled capsaicin in our study has 
been confirmed in our previous study which showed that the β2-adenoceptor 
agonist procaterol did not alter the number of coughs induced by inhaled 
capsaicin, while completely inhibiting the capsaicin-induced increase in airway 
resistance 24 h after an antigen challenge in this model [6]. 
In this study, the doses of macrolides were found to be significantly greater 
than those used to treat human diseases. These doses were required to define 
whether or not macrolides have the potential to inhibit cough reflex 
hypersensitivity, because they were the maximal doses of macrolides 
systemically administrated among previous in vivo studies [23-25] we searched. 
The present study showed for the first time that EM, a 14-membered macrolide, 
dose-dependently inhibited the increase in the cough reflex sensitivity to inhaled 
capsaicin and the total number of cells in the BALF that developed 48 h after 
antigen challenge in the actively sensitized guinea pigs, but not in the naïve 
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 animals. Likewise, AZM, a 15-membered macrolide, also reduced the 
antigen-induced increase in the cough reflex sensitivity and the total number of 
cells in the BALF. In contrast, JM, a 16-membered macrolide, did not influence 
either the antigen-induced increase in the cough reflex sensitivity or the total 
number of cells in the BALF. The analysis of the BALF demonstrated that EM 
dose-dependently reduced the antigen-induced increase in SP, PGE2 and LTBB4, 
but not the TXB2 or histamine, levels in the BALF. Moreover, the inhibitory effect 
of EM on the antigen-induced increase in the SP levels in BALF was not followed 
by the restoration of the antigen-induced decrease in NEP, a major 
SP-degrading enzyme, activity in the tracheal tissue. This result indicates that 
EM reduced the release of SP, while not recovering the ability of SP degradation. 
Coughing is initiated when the afferent nerve impulse activity is increased. 
Several findings suggest that the capsaicin-induced cough is mediated mainly by 
the activation of the transient receptor potential vanilloid type channel-1 (TRPV1), 
a capsaicin receptor on the terminal of the nonmyelinated C-fibers which 
subsequently release the sensory neuropeptides, such as tachykinins (SP, 
neurokinin A, and neurokinin B). These tachykinins have been known to act on 
NK receptors on the afferent nerves, denoted NK1, NK2 and NK3, which have the 
highest affinity for SP, neurokinin A and neurokinin B, respectively, to mediate 
many airway responses, including gland secretion and increased vascular 
permeability. However, the precise role of SP in the peripheral initiation of the 
cough reflex still remains controversial. Several studies have shown that the 
exposure of guinea pigs to SP or NEP inhibitor induced a cough response [26, 
27], while other controversial data have been obtained about the influence of 
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 aerosolized SP, which induced no direct effect on cough reflex sensitivity of 
guinea pigs [28] or pigs [29]. On the other hand, Katsumata and coworkers [30] 
have reported that inhaled SP induced cough in patients with upper airway 
infection, but not in healthy subjects. In addition, it has been shown that both the 
NK1 receptor antagonist FK888 and the dual NK1 and NK2 peptide receptor 
antagonists FK224 significantly inhibited the increase in cough response to 
inhaled capsaicin in different types of guinea pig models of cough with allergic 
airway inflammation [31-33]. In our laboratory, we previously showed in the 
actively sensitized guinea pigs that the increase in the cough reflex sensitivity 
after an antigen challenge is correlated with increase in the SP levels in the 
BALF [18] and the decrease in the NEP activity in the tracheal tissue [19], which 
are consistent with the results in the present study. Taken together, these 
findings suggest that the role of peripheral SP in cough reflex sensitivity may be 
different between species and/or employed experimental systems, especially 
presence of airway inflammation. We believe that at least the antigen-induced 
increase in the cough response to capsaicin is associated with the results from 
the increase of SP. Furthermore, the findings that EM reduced SP in BALF and 
the increase of the cough reflex sensitivity following antigen challenge are 
therefore considered to support our standpoints. 
In addition, we also found in this study that EM dose-dependently inhibited 
the antigen-induced release of PGE2 in the BALF (as is shown in a previous 
study [34]) and this was correlated with the decrease in cough reflex sensitivity. 
PGE2 is a cyclooxygenase (COX)-2 metabolite of arachidonic acid released from 
the airway epithelium and smooth muscles during airway inflammatory reaction 
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 including NAEB [7]. There are several reports demonstrating that the number of 
capsaicin-induced coughs is increased in the presence of prostaglandins in the 
airway [35, 36], furthermore, several other lines of evidence indicate that PGE2 
in the airway affects the cough reflex sensitivity via enhancing the sensitivity of 
the C-fibers to capsaicin, but does not directly stimulate the afferent fibers to 
induce cough [5, 37, 38]. The results that EM reduced the PGE2 levels in BALF 
and cough reflex sensitivity simultaneously support the sensitizing effect of PGE2 
on C-fibers to capsaicin. 
The increased vascular permeability and the subsequent interstitial airway 
edema evoked by the released SP and PGE2 in the airways [39] may also 
stimulate and activate the afferent sensory nerves [40]. Our result, in which the 
antigen-induced increase in the total number of cells, but not cell components, in 
the BALF was decreased by the treatment with EM, suggests the suppressive 
effects of EM on the antigen-induced increase of vascular permeability via SP or 
PGE2.  
However, in this study, even though EM had a maximal anti-tussive effect at 5 
mg/kg, there was no difference between the animals treated at this dose of EM 
and PC group with respect to SP or PGE2, with the only difference in LTBB4. LTB4B  
is a lipoxygenase metabolite of arachidonic acid, which is also released during 
airway inflammation similar to PGE2. Although the effects of EM on LTBB4 in 
neutrophilic inflammatory reaction have been shown in several studies, in the 
present study we showed for the first time that EM inhibited the increase of LTB4B  
in the eosinophilic inflammatory reaction, while the observed reduction of LTB4 
by EM was correlated with the number of coughs. This result suggests that LTBB4 
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 rather than SP and PGE2 may thus be involved in the effect of EM on the cough 
reflex sensitivity in this model. A recent study showed that LTB4B  directly activates 
TRPV1 and promotes the release of SP from the C-fibers in vitro [41]. However, 
as far as we could determine based on an extensive literature search, there are 
no reports concerning the role of LTB4 in the cough reflex hypersensitivity 
associated with airway eosinophilic inflammation. Further studies are necessary 
to elucidate the relationship between LTBB4 and cough reflex sensitivity. 
On the other hand, we also measured the histamine levels in BALF. 
Histamine is a biogenic amin that is mainly released from mast cells and 
basophils. Moreover, it is considered to be a potent and direct activator of the 
afferent sensory nerves [8] and, therefore, the use of antihistamines has been 
recommended for the treatment of AC, thus resulting in the normalization of the 
cough reflex sensitivity. Our results showed that the antigen-induced increase in 
the histamine levels in the BALF was not affected by the administration of EM, 
despite a normalization of the cough reflex sensitivity. These results suggest that 
EM and antihistamine normalize the cough reflex sensitivity by different 
mechanisms. Therefore, the additional administration of EM may be effective in 
the treatment of atopic cough when the antihistamines alone are insufficient. 




The present study clearly showed that 14- and 15-membered, but not 
16-membered, macrolides have a potent antitussive effect in antigen-induced 
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 eosinophilic airway inflammation. This antitussive action of EM may result from 
the suppressive effect of EM on the afferent sensory nerves by inhibiting 
antigen-induced release of afferent sensory nerve sensitizers, such as LTBB4 and 
partly SP and PGE2 in the airways and by decreasing the subsequent vascular 
permeability. These results suggest that 14- and 15-membered macrolides may 
provide a therapeutic benefit in patients with allergic airway disorders, in which 
the cough reflex sensitivity is observed to be increased, such as non-asthmatic 
eosinophilic bronchitis and atopic cough. 
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 Table 1   Effects of EM (A), AZM (B) and JM (C) on cellular accumulation in 
BALF 48 h after challenge with an antigen in actively sensitized guinea pigs. 
Negative control, the animals received a challenge with saline and were 
intraperitoneally administered saline; Positive control, the animals received a 
challenge with OA and were intraperitoneally administered saline; Mac, macrophages; 
Neu, neutrophils; Lym, lymphocytes; Eos, eosinophils; #P < 0.01 vs. negative control; 
†P < 0.05, ‡P < 0.01 vs. positive control, respectively. Experiments A, B and C are 





Mac Neu Lym Eos 
A      
Negative control 18.1 ± 0.3 84.6 ± 3.9 0.3 ± 0.2 3.1 ± 0.3 12.1 ± 3.9 
Positive control 112.9 ±1.0# 27.5 ± 2.0# 6.0 ± 0.9# 2.7 ± 0.7 63.8 ± 2.6#
EM 0.5 mg/kg 80.8 ± 0.9† 31.3 ± 3.2 10.4 ± 1.6† 2.4 ±0.6 55.8 ± 4.2 
EM 5 mg/kg 73.1 ± 0.7‡ 30.8 ± 3.2 8.3 ± 1.0 2.0 ± 0.4 58.8 ± 3.7 
EM 50 mg/kg 50.6 ± 0.8‡ 27.8 ± 1.2 6.3 ± 1.0 1.7 ± 0.3 64.2 ± 1.9 
B      
Negative control 16.5 ± 0.3 89.8 ± 2.4 0.1 ± 0.1 3.2 ± 0.3 7.0 ± 2.6 
Positive control 91.5 ± 1.5# 33.8 ± 3.7# 7.2 ± 2.1# 2.8 ± 0.7 56.2 ± 3.8#
AZM 50 mg/kg 31.1 ± 0.5‡ 40.5 ± 3.9 6.4 ± 1.0 1.9 ± 0.6 51.2 ± 3.8 
C      
Negative control 18.1 ± 0.3 84.3 ± 5.0 0.4 ± 0.3 3.1 ± 0.3 12.3 ± 5.0 
Positive control 67.2 ± 0.7# 27.9 ± 2.4# 3.9 ± 0.6# 2.9 ± 0.5 65.2 ± 2.5#
JM 50 mg/kg 71.2 ± 0.7 26.5 ± 2.3 6.0 ± 1.7 1.4 ± 0.3† 66.5 ± 3.0 
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